NCT01099774

Safety and Efficacy of Different Formulations of Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 597 (actual)
• Sponsor: Allergan · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study will evaluate the safety and efficacy of bimatoprost 0.03% formulation B ophthalmic solution with LUMIGAN® (bimatoprost ophthalmic solution 0.03%) once daily for 12 weeks in patients with glaucoma or ocular hypertension

Conditions

• Glaucoma
• Ocular Hypertension

Interventions

Type	Name	Description
DRUG	Bimatoprost 0.03% Formulation B Ophthalmic Solution	One drop administered in each eye, every evening, for 12 weeks
DRUG	Bimatoprost 0.03% Ophthalmic Solution	One drop administered in each eye, every evening, for 12 weeks

Timeline

• Start date: 2010-05-01
• Primary completion: 2011-04-29
• Completion: 2011-04-29
• First posted: 2010-04-08
• Last updated: 2019-04-17
• Results posted: 2012-04-27

Locations

1 site across 1 country: United States